Biotech startup Kite Pharma has raised $35m for cancer-fighting technologies in a series A round backed by a syndicate of investors. The Los Angeles-based startup announced that it has closed $20m in new funds, as well as converting $15m in outstanding promissory notes into series A preferred stock. Life science VC Alta Partners, VC firm…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.